Intellia Therapeutics Inc sell geldnutzer
Start price
25.12.25
/
60%
€7.90
Target price
25.12.26
€6.00
Performance (%)
40.72%
End price
11:01
€11.12
Summary
This prediction ended on 11:01 with a price of €11.12. The SELL prediction by geldnutzer for Intellia Therapeutics Inc was trending in the completely wrong direction and closed with a performance of 40.72%. geldnutzer has a follow-up prediction for Intellia Therapeutics Inc, but this time predicts that Intellia Therapeutics Inc is a Buy. geldnutzer has 60% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -1.880% | -1.880% |
| iShares Core DAX® | -0.471% | 0.925% |
| iShares Nasdaq 100 | 4.192% | 15.863% |
| iShares Nikkei 225® | -0.073% | 8.098% |
| iShares S&P 500 | 2.680% | 8.747% |
According to geldnutzer what are the pros and cons of Intellia Therapeutics Inc for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
Little Investments for future growth
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Below average Management
Bad culture
Little innovation
Few uniques
Dependend from some customers or products
Growths slower than the competition
high free float
Below average Marketposition
Significant cyclical dependencies
Unknown brand
Business model of the past or high risk
Sustainability is not important
Higher risks for its business
Comments by geldnutzer for this prediction
In the thread Intellia Therapeutics Inc diskutieren
In the thread Trading Intellia Therapeutics Inc
Current prediction by geldnutzer for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.12
11:01
11:01
€12.00
15.05.27
15.05.27
-0.18%
12:40
12:40
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
